Autologous peripheral blood stem cell transplantation for acute myelogenous leukemia

H. Gondo, M. Harada, Toshihiro Miyamoto, Katsuto Takenaka, K. Tanimoto, S. Mizuno, T. Fujisaki, K. Nagafuji, S. Hayashi, T. Eto, S. Taniguchi, Koichi Akashi, N. Harada, K. Yamasaki, T. Shibuya, E. Matsuishi, Y. Ohno, S. Makino, Y. Takamatsu, M. MurakawaT. Teshima, Y. Hirota, T. Okamura, N. Kinukawa, S. Inaba, Y. Niho

Research output: Contribution to journalArticle

59 Citations (Scopus)

Abstract

The safety and efficacy of myeloablative therapy followed by autologous peripheral blood stem cell transplantation (ABSCT) for acute myelogenous leukemia (AML) were evaluated in 60 patients. Peripheral blood stem cells (PBSC) were collected during recovery after consolidation chemotherapy. High-dose chemotherapy consisting of busulfan (16 mg/kg), etoposide (40 mg/kg), and cytosine arabinoside (3g/m2x4) (BEA regimen) was used for pretransplant conditioning in 13 patients. For the remaining 47 patients, granulocyte colony-stimulating factor (G-CSF) was administered concurrently with the BEA regimen during conditioning. Unpurged, cryopreserved PBSC containing a median number of 5.4 x 108 MNC/kg or 12 x 104 CFU-GM/kg were reinfused at transplantation. The median number of days to granulocytes exceeding 500/μl and last platelet transfusion were 15 (8-44) and 24 (0- > 180), respectively. The 3-year probabilities of disease-free survival (DFS) and relapse were 78.6 and 21.4% for patients transplanted in first remission, 29.6 and 64.4% for those in second or third remission, and 11.1 and 77.8% for those in relapse, respectively. There were no transplant-related deaths within 100 days of transplantation. Age, disease status at transplantation, and number of induction chemotherapies to first complete remission were risk factors affecting the outcome of ABSCT. These results of ABSCT for AML in first remission warrant a prospective study of ABSCT as post-remission therapy.

Original languageEnglish
Pages (from-to)821-826
Number of pages6
JournalBone Marrow Transplantation
Volume20
Issue number10
DOIs
Publication statusPublished - Nov 2 1997

Fingerprint

Peripheral Blood Stem Cell Transplantation
Acute Myeloid Leukemia
Transplantation
Consolidation Chemotherapy
Recurrence
Busulfan
Platelet Transfusion
Granulocyte-Macrophage Progenitor Cells
Induction Chemotherapy
Cytarabine
Granulocyte Colony-Stimulating Factor
Etoposide
Granulocytes
Disease-Free Survival
Prospective Studies
Transplants
Safety
Drug Therapy
Therapeutics
Peripheral Blood Stem Cells

All Science Journal Classification (ASJC) codes

  • Hematology
  • Transplantation

Cite this

Autologous peripheral blood stem cell transplantation for acute myelogenous leukemia. / Gondo, H.; Harada, M.; Miyamoto, Toshihiro; Takenaka, Katsuto; Tanimoto, K.; Mizuno, S.; Fujisaki, T.; Nagafuji, K.; Hayashi, S.; Eto, T.; Taniguchi, S.; Akashi, Koichi; Harada, N.; Yamasaki, K.; Shibuya, T.; Matsuishi, E.; Ohno, Y.; Makino, S.; Takamatsu, Y.; Murakawa, M.; Teshima, T.; Hirota, Y.; Okamura, T.; Kinukawa, N.; Inaba, S.; Niho, Y.

In: Bone Marrow Transplantation, Vol. 20, No. 10, 02.11.1997, p. 821-826.

Research output: Contribution to journalArticle

Gondo, H, Harada, M, Miyamoto, T, Takenaka, K, Tanimoto, K, Mizuno, S, Fujisaki, T, Nagafuji, K, Hayashi, S, Eto, T, Taniguchi, S, Akashi, K, Harada, N, Yamasaki, K, Shibuya, T, Matsuishi, E, Ohno, Y, Makino, S, Takamatsu, Y, Murakawa, M, Teshima, T, Hirota, Y, Okamura, T, Kinukawa, N, Inaba, S & Niho, Y 1997, 'Autologous peripheral blood stem cell transplantation for acute myelogenous leukemia', Bone Marrow Transplantation, vol. 20, no. 10, pp. 821-826. https://doi.org/10.1038/sj.bmt.1700979
Gondo, H. ; Harada, M. ; Miyamoto, Toshihiro ; Takenaka, Katsuto ; Tanimoto, K. ; Mizuno, S. ; Fujisaki, T. ; Nagafuji, K. ; Hayashi, S. ; Eto, T. ; Taniguchi, S. ; Akashi, Koichi ; Harada, N. ; Yamasaki, K. ; Shibuya, T. ; Matsuishi, E. ; Ohno, Y. ; Makino, S. ; Takamatsu, Y. ; Murakawa, M. ; Teshima, T. ; Hirota, Y. ; Okamura, T. ; Kinukawa, N. ; Inaba, S. ; Niho, Y. / Autologous peripheral blood stem cell transplantation for acute myelogenous leukemia. In: Bone Marrow Transplantation. 1997 ; Vol. 20, No. 10. pp. 821-826.
@article{237f35afd7c3460bb1a8ed1555eacf52,
title = "Autologous peripheral blood stem cell transplantation for acute myelogenous leukemia",
abstract = "The safety and efficacy of myeloablative therapy followed by autologous peripheral blood stem cell transplantation (ABSCT) for acute myelogenous leukemia (AML) were evaluated in 60 patients. Peripheral blood stem cells (PBSC) were collected during recovery after consolidation chemotherapy. High-dose chemotherapy consisting of busulfan (16 mg/kg), etoposide (40 mg/kg), and cytosine arabinoside (3g/m2x4) (BEA regimen) was used for pretransplant conditioning in 13 patients. For the remaining 47 patients, granulocyte colony-stimulating factor (G-CSF) was administered concurrently with the BEA regimen during conditioning. Unpurged, cryopreserved PBSC containing a median number of 5.4 x 108 MNC/kg or 12 x 104 CFU-GM/kg were reinfused at transplantation. The median number of days to granulocytes exceeding 500/μl and last platelet transfusion were 15 (8-44) and 24 (0- > 180), respectively. The 3-year probabilities of disease-free survival (DFS) and relapse were 78.6 and 21.4{\%} for patients transplanted in first remission, 29.6 and 64.4{\%} for those in second or third remission, and 11.1 and 77.8{\%} for those in relapse, respectively. There were no transplant-related deaths within 100 days of transplantation. Age, disease status at transplantation, and number of induction chemotherapies to first complete remission were risk factors affecting the outcome of ABSCT. These results of ABSCT for AML in first remission warrant a prospective study of ABSCT as post-remission therapy.",
author = "H. Gondo and M. Harada and Toshihiro Miyamoto and Katsuto Takenaka and K. Tanimoto and S. Mizuno and T. Fujisaki and K. Nagafuji and S. Hayashi and T. Eto and S. Taniguchi and Koichi Akashi and N. Harada and K. Yamasaki and T. Shibuya and E. Matsuishi and Y. Ohno and S. Makino and Y. Takamatsu and M. Murakawa and T. Teshima and Y. Hirota and T. Okamura and N. Kinukawa and S. Inaba and Y. Niho",
year = "1997",
month = "11",
day = "2",
doi = "10.1038/sj.bmt.1700979",
language = "English",
volume = "20",
pages = "821--826",
journal = "Bone Marrow Transplantation",
issn = "0268-3369",
publisher = "Nature Publishing Group",
number = "10",

}

TY - JOUR

T1 - Autologous peripheral blood stem cell transplantation for acute myelogenous leukemia

AU - Gondo, H.

AU - Harada, M.

AU - Miyamoto, Toshihiro

AU - Takenaka, Katsuto

AU - Tanimoto, K.

AU - Mizuno, S.

AU - Fujisaki, T.

AU - Nagafuji, K.

AU - Hayashi, S.

AU - Eto, T.

AU - Taniguchi, S.

AU - Akashi, Koichi

AU - Harada, N.

AU - Yamasaki, K.

AU - Shibuya, T.

AU - Matsuishi, E.

AU - Ohno, Y.

AU - Makino, S.

AU - Takamatsu, Y.

AU - Murakawa, M.

AU - Teshima, T.

AU - Hirota, Y.

AU - Okamura, T.

AU - Kinukawa, N.

AU - Inaba, S.

AU - Niho, Y.

PY - 1997/11/2

Y1 - 1997/11/2

N2 - The safety and efficacy of myeloablative therapy followed by autologous peripheral blood stem cell transplantation (ABSCT) for acute myelogenous leukemia (AML) were evaluated in 60 patients. Peripheral blood stem cells (PBSC) were collected during recovery after consolidation chemotherapy. High-dose chemotherapy consisting of busulfan (16 mg/kg), etoposide (40 mg/kg), and cytosine arabinoside (3g/m2x4) (BEA regimen) was used for pretransplant conditioning in 13 patients. For the remaining 47 patients, granulocyte colony-stimulating factor (G-CSF) was administered concurrently with the BEA regimen during conditioning. Unpurged, cryopreserved PBSC containing a median number of 5.4 x 108 MNC/kg or 12 x 104 CFU-GM/kg were reinfused at transplantation. The median number of days to granulocytes exceeding 500/μl and last platelet transfusion were 15 (8-44) and 24 (0- > 180), respectively. The 3-year probabilities of disease-free survival (DFS) and relapse were 78.6 and 21.4% for patients transplanted in first remission, 29.6 and 64.4% for those in second or third remission, and 11.1 and 77.8% for those in relapse, respectively. There were no transplant-related deaths within 100 days of transplantation. Age, disease status at transplantation, and number of induction chemotherapies to first complete remission were risk factors affecting the outcome of ABSCT. These results of ABSCT for AML in first remission warrant a prospective study of ABSCT as post-remission therapy.

AB - The safety and efficacy of myeloablative therapy followed by autologous peripheral blood stem cell transplantation (ABSCT) for acute myelogenous leukemia (AML) were evaluated in 60 patients. Peripheral blood stem cells (PBSC) were collected during recovery after consolidation chemotherapy. High-dose chemotherapy consisting of busulfan (16 mg/kg), etoposide (40 mg/kg), and cytosine arabinoside (3g/m2x4) (BEA regimen) was used for pretransplant conditioning in 13 patients. For the remaining 47 patients, granulocyte colony-stimulating factor (G-CSF) was administered concurrently with the BEA regimen during conditioning. Unpurged, cryopreserved PBSC containing a median number of 5.4 x 108 MNC/kg or 12 x 104 CFU-GM/kg were reinfused at transplantation. The median number of days to granulocytes exceeding 500/μl and last platelet transfusion were 15 (8-44) and 24 (0- > 180), respectively. The 3-year probabilities of disease-free survival (DFS) and relapse were 78.6 and 21.4% for patients transplanted in first remission, 29.6 and 64.4% for those in second or third remission, and 11.1 and 77.8% for those in relapse, respectively. There were no transplant-related deaths within 100 days of transplantation. Age, disease status at transplantation, and number of induction chemotherapies to first complete remission were risk factors affecting the outcome of ABSCT. These results of ABSCT for AML in first remission warrant a prospective study of ABSCT as post-remission therapy.

UR - http://www.scopus.com/inward/record.url?scp=0030831841&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030831841&partnerID=8YFLogxK

U2 - 10.1038/sj.bmt.1700979

DO - 10.1038/sj.bmt.1700979

M3 - Article

C2 - 9404921

AN - SCOPUS:0030831841

VL - 20

SP - 821

EP - 826

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

SN - 0268-3369

IS - 10

ER -